NEWS

Written by: Michelle Phillips, PharmD, BCOP, Wilmot Cancer Center Download Here Description: The purpose of this PQI is a summary of process for initiating and monitoring darolutamide therapy in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).   Background: Darolutamide is a next-generation androgen receptor antagonist approved in 2019 for the treatment of […]

Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology Download Here Description: This PQI will review appropriate patient identification and management techniques to ensure optimal benefit from telotristat ethyl therapy. Background: A first in class oral tryptophan hydroxylase inhibitor, telotristat ethyl, is approved for use in combination with somatostatin analogues (SSA) therapy in […]

Written by: Matthew Schulz, RPh Rocky Mountain Cancer Centers Download Here Description of PQI: The purpose of this PQI is to identify patients initiating everolimus therapy and could benefit from stomatitis prophylaxis with a steroid mouthwash. Background: Stomatitis is a significant complication associated with mTOR inhibition. In BOLERO-2 patients receiving everolimus/exemestane (EVE/EXE), all grade stomatitis […]

Written By: Jon Suyko Pharm.D., BCPS, UC Health Highlands Ranch DOWNLOAD HERE Description: The purpose of this PQI is to discuss the various indications for rucaparib (Rubraca). Background: Rucaparib is an oral tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) PARP 1, PARP 2 and PARP 3, with antineoplastic activity.1 PARPs are a group of […]

Written By: Samantha Larson, PharmD, M Health Fairview Download Here Positive Quality Intervention: Enzalutamide (Xtandi) In Castration-Resistant Prostate Cancer or Metastatic Castration-Sensitive Prostate Cancer Description: The purpose of this PQI is a summary of process for initiating and monitoring enzalutamide therapy in patients with either castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer (mCSPC).1 Background: […]

Written By: Autumn Alvarez, PharmD, BCPS, Blue Ridge Cancer Care Download Here Description:  The purpose of this PQI is to describe the indication, pharmacology and dosing of trilaciclib. Background: Trilaciclib is a CDK 4/6 inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in patients undergoing chemotherapy with a platinum/etoposide or topotecan containing regimen for […]

Written By: Luis E. Raez, MD, FACP Memorial Healthcare System DOWNLOAD HERE Description: The purpose of this PQI is to evaluate the use of lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer  with disease progression on or after platinum-based chemotherapy. Background: Small cell lung cancer (SCLC), which accounts for around […]

FOR IMMEDIATE RELEASE SEPTEMBER 1, 2021 Media Contact: Katie Edmiston | Marketing Manager Katie.Edmiston@NCODA.org   NCODA Expands Patient and Caregiver Resource to Improve Understanding and Outcomes CAZENOVIA, NY – September 1, 2021 – With the success of the highly utilized NCODA conceived OCE (Oral Chemotherapy Education) online resource, the collaboration with the Oncology Nursing Society […]

Written By: Doug Braun, PharmD and Emily Gallagher, PharmD | AON Download Here This PQI serves to review the use of the combination product Akynzeo® for patients with acute and delayed chemotherapy-induced nausea and vomiting (CINV). Background1-5: Nausea and vomiting from chemotherapy can occur acutely (within 24 hours) or have a more delayed onset (>24 […]

FOR IMMEDIATE RELEASE AUGUST 10, 2021    NCODA Structures Medically Integrated Pharmacy Accreditation   Cazenovia, New York – As the leading not-for-profit association for the patient-centered medically-integrated oncology community, NCODA, Inc. is excited to announce the new NCODA Center of Excellence (CoE) Medically Integrated Pharmacy (MIP) Accreditation Program. The program, based on compliance with the […]

FOR IMMEDIATE RELEASE August 9th 2021 STATEMENT FROM NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org BIDEN ADMINISTRATION PROPOSES WITHDRAW FROM MOST FAVORED NATION   NCODA has been in opposition of the Most Favored Nation (MFN) model for Medicare patients since it […]

Florida Cancer Specialists & Research Institute to mandate COVID-19 vaccines for its workforce Increasing vaccination rates essential to protecting patients and staff Fort Myers, Fla., Aug. 3, 2021 — In response to growing concerns amidst the statewide surge of COVID-19 variants, Florida Cancer Specialists & Research Institute (FCS) will require all physicians and team members obtain their first […]